NEW YORK (GenomeWeb News) – IntelligentMDx said today that it has entered into a development and licensing agreement to design, develop, and manufacture CE-marked and US Food and Drug Administration-cleared diagnostic tests for use on Qiagen's QIAsymphony RGQ platform.

IMDx did not disclose the assays, but said they will be incorporated into Qiagen's growing portfolio of molecular diagnostic assays and be distributed worldwide by Qiagen. Qiagen also retained the rights to manufacture the assays pursuant to volume considerations, IMDx said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by

This webinar will discuss how acoustic liquid handling can reduce the time and costs for labs performing carrier screening with next-generation sequencing.

Sponsored by

This webinar will discuss a new approach to amplicon sequencing that addresses the current inefficiencies of the method, such as small designs, primer drop outs, and low uniformity.

Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

Sponsored by

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.